INCY vs MRNA
Incyte vs Moderna — AI-powered side-by-side comparison
| Metric | INCY | MRNA |
|---|
| AI Score |
70
|
61
|
| Price |
$129.73
|
$158.81
|
| P/E Ratio |
15.74×
|
-17.40×
|
| ROE |
24.9%
|
-32.6%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
92.6%
|
-12.6%
|
| Debt / Equity |
0.01×
|
0.19×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
71.7
|
68.6
|
| Beta |
0.769
|
0.899
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for INCY versus MRNA.
INCY leads by 9 points.
INCY scores 70/100 (Buy) versus MRNA at 61/100 (Buy).
INCY Committee View
100% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- ROE of 29.6% shows genuine earnings power backing the valuation — Value
- Revenue growing 26.9% YoY -- genuine top-line momentum — Growth
- EPS growing 80.3% YoY — Growth
Bear Case
- RSI at 72 is in overbought territory — Technical
- Weekly RSI at 81 -- overbought on the larger timeframe too — Technical
MRNA Committee View
67% agreement
6 analysts
The primary driver is price structure making higher highs and higher lows. The main limiting factor is bollinger bandwidth of 194.9% signals elevated volatility. The committee is constructive but not yet at full conviction.
Bull Case
- Price-to-book of 1.3x is a discount to asset value — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- ROE of only -39.2% -- cheap may mean cheap for a reason — Value
- Revenue declining -27.6% YoY -- this is not a growth story right now — Growth
- Weekly RSI at 82 -- overbought on the larger timeframe too — Technical